¿Ha cambiado nuestra idea del remodelado bronquial en asma?

NURIA MARINA, ANA GOMEZ, ANA GOMEZ, EDURNE ECHEVARRIA, EDURNE ECHEVARRIA

Resumen


El asma es una enfermedad inflamatoria crónica de las vías respiratorias que se caracteriza por obstrucción del flujo aéreo. La remodelación de las vías respiratorias es una característica presente, incluso en estadios leves de la enfermedad. Se caracteriza por un cambio de composición, contenido y distribución de componentes celulares y moleculares en la pared de la vía aérea. El remodelado contribuye a la pérdida de función pulmonar, además de un mal control de la enfermedad. Existen terapias que pueden abordar esta característica, sobre todo los tratamientos biológicos, pero son necesarias futuras investigaciones para aclarar esta cuestión. Asimismo, el término de “remisión del asma” ha empezado a aparecer en artículos científicos, pero debe definirse con exactitud en esta patología. Aun así, reconociendo las opciones terapéuticas actuales y evaluando el horizonte prometedor de la investigación, podríamos estar cerca de alcanzar el objetivo de la mejoría del remodelado bronquial, conllevando incluso, una remisión en el manejo del asma.


Texto completo:

HTML PDF

Referencias


Benayoun L, Druilhe A, Dombret MC, Aubier M and Petrolanni M. Airway Structural Alterations Selectively Associated with Severe Asthma. Am J Respir Crit Care Med. 2003 May 15;167(10):1360-8.

Halwani R, Al-Muhsen S, Hamid Q. Airway remodeling in asthma. Curr Opin Pharmacol. (2010) 10:236–45.

Su ZQ, Zhou ZQ, Guan WJ, Fan MY, Rao WY et al. Airway remodeling and bronchodilator responses in asthma assessed by endobronchial optical coherence tomography. Allergy. 2022 Feb;77(2):646-649.

Varricchi G, Ferri S, Pepys J, Poto R, Spadaro G, Nappi E, Paoletti G, Virchow JC, Heffler E, Canonica WG. Biologics and airway remodeling in severe asthma. Allergy. 2022 Aug 11.

Cohen L, Xueping E, Tarsi J, et al. Epithelial cell proliferation contributes to airway remodeling in severe asthma. Am J Respir Crit Care Med 2007; 176: 138–145.

Chung KF, Wenzel SE, Brozek JL, Bush A, Castri M et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43: 343–373.

Bergeron C, Boulet L-P. Structural changes in airway diseases. Chest. (2006) 129:1068–87. doi: 10.1378/chest.129.4.1068

Elliot JG, Jones RL, Abramson MJ, et al. Distribution of airway smooth muscle remodelling in asthma: relation to airway in inflammation. Respirology 2015;20:66-72.

Pascual RM, Peters SP. Airway remodeling contributes to the progressive loss of lung function in asthma: an overview. J Allergy Clin Immunol 2005;116:477-486; quiz 487.

Bergeron C, Boulet LP. Structural changes in airway diseases: characteristics, mechanisms, consequences, and pharmacologic modulation. Chest 2006;129:1068-1087.

Hough KP, Curtiss ML, Blain TJ, et al. Airway Remodeling in Asthma. Front Med (Lau-sanne)2020;7:191.

Holgate ST. Pathogenesis of asthma. Clin Exp Allergy 2008;38:872-897.

Winkler T, Frey U. Airway remodeling: Shifting the trigger point for exacerbations in asthma.J Allergy Clin Immunol 2021;148:710-712.

Chetta A, Zanini A, Foresi A, et al. Vascular component of airway remodeling in asthma is reduced by high dose of fluticasone. Am J Respir Crit Care Med 2003;167:751-757.

Prakash YS, Halayko AJ, Gosens R, Panettieri RA, Camoretti-Mercado B. An Official American Thoracic Society Research Statement: Current Challenges Facing Research and Therapeutic Advances in Airway Remodeling. Am J Respir Crit Care Med. 2017 Jan 15;195(2):e4-e19.

Grainge CL, Lau LC, Ward JA, Dulay V, Lahiff G, Wilson S, Holgate S, Davies DE, Howarth PH. Effect of bronchoconstriction on airway remodeling in asthma.NEngl JMed. 2011;364:2006–15.

Todorova L, Gurcan E, Miller-Larsson A, Westergren-Thorsson G. Lung fibroblast proteoglycan production induced by serum is inhibited by budesonide and formoterol. Am J Respir Cell Mol Biol. 2006;34:92–100.

Henderson WR Jr, Tang LO, Chu SJ, Tsao SM, Chiang GK, Jones F, Jonas M, Pae C, Wang H, Chi EY. A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am J Respir Crit Care Med. 2002;165:108–16.

Gobbato NB, de Souza FC, Fumagalli SB, Lopes FD, Prado CM, Martins MA, Tiberio Ide F, Leick EA. Antileukotriene reverts the early effects of inflammatory response of distal parenchyma in experimental chronic allergic inflammation. Biomed Res Int. 2013;2013:523761.

Bos IS, Gosens R, Zuidhof AB, Schaafsma D, Halayko AJ, Meurs H, Zaagsma J. Inhibition of allergen-induced airway remodelling by tiotropium and budesonide: a comparison. Eur Respir J. 2007;30:653–61.

Ohta S, Oda N, Yokoe T, Tanaka A, Yamamoto Y, Watanabe Y, Minoguchi K, Ohnishi T, Hirose T, Nagase H, Ohta K, Adachi M. Effect of tiotropium bromide on airway inflammation and remodelling in a mouse model of asthma. Clin Exp Allergy. 2010;40:1266–75.

Jendzjowsky N., Laing A., Malig M., Matyas J., de Heuvel E., et al. Long-term modulation of airway remodelling in severe asthma following bronchial thermoplasty. European Respiratory Journal 2022 59:1

Ichikawa T, Panariti A, Audusseau S, Mogas AK, Olivenstein R. Effect of bronchial thermoplasty on structural changes and inflammatory mediators in the airways of subjects with severe asthma. Respir Med. 2019 Apr;150:165-172.

Sadeghdoust M, Mirsadraee M, Aligolighasemabadi F, Khakzad MR, Attar AH et al. Effect of azithromycin on bronchial wall thickness in severe persistent asthma: A double-blind placebo-controlled randomized clinical trial. Respir Med. 2021 Aug-Sep;185:106494.

Gupta A, Sjoukes A, Richards D, Banya W, Hawrylowicz C, Bush A, Saglani S. Relationship between serum vitamin D, disease severity, and airway remodeling in children with asthma. Am J Respir Crit Care Med. 2011;184:1342–9.

Damera G, Fogle HW, Lim P, Goncharova EA, Zhao H, Banerjee A, Tliba O, Krymskaya VP, Panettieri RA Jr. Vitamin D inhibits growth of human airway smooth muscle cells through growth factor-induced phosphorylation of retinoblastoma protein and checkpoint kinase 1. Br J Pharmacol. 2009;158:1429–41.

Casale TB, Luskin AT, Busse W, et al. Omalizumab E

ectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study. J Allergy Clin Immunol Pract 2019;7:156-164 e151.

Riccio AM, Dal Negro RW, Micheletto C, et al. Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients. Int J Immunopathol Pharmacol2012;25:475-484.

Zastrzezynska W, Przybyszowski M, Bazan-Socha S, et al. Omalizumab may decrease the thickness of the reticular basement membrane and bronectin deposit in the bronchial mucosa of severe allergic asthmatics. J Asthma 2020;57:468-477.

Zastrzeżyńska W, Bazan-Socha S, Przybyszowski M, Gawlewicz-Mroczka A, Jakieła B et al. Effect of omalizumab on bronchoalveolar lavage matrix metalloproteinases in severe allergic asthma. Journal of Asthma (2022) 59:6 (1087-1094).

Solidoro P, Patrucco F, de Blasio F, Brussino L, Bellocchia M et al. Predictors of reversible airway obstruction with omalizumab in severe asthma: a real-life study. Ther Adv Respir Dis. 2019; 13:1-12.

Hoshino M, Ohtawa J. Effects of adding omalizumab, an antiimmunoglobulin E antibody, on airway wall thickening in asthma. Respiration. (2012) 83:520–8. doi: 10.1159/000334701

Flood-Page P, Menzies-Gow A, Phipps S, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003;112:1029-1036.

Przybyszowski M, Gross-Sondej I, Zarychta J, Bazan-Socha S, Bochenek G et al. Late Breaking Abstract - The impact of treatment with mepolizumab on airway remodeling in patients with severe eosinophilic asthma. European Respiratory Journal 2021 58.

Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. (2009) 360:973–84. doi: 10.1056/NEJMoa0808991

Varricchi G, Senna G, Loffredo S, Bagnasco D, Ferrando M, Canonica GW. Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine? Front Immunol 2017;8:242.

Rial MJ, Cañas JA, Rodrigo-Muñoz JM, Valverde-Monge M, Sastre B et al. Changes in serum microRNAs after anti-IL-5 biological treatment of severe asthma. Int J Mol Sci. 2021 Mar 30;22(7):3558.

Chachi L, Diver S, Kaul H, et al. Computational modelling prediction and clinical validation of impact of benralizumab on airway smooth muscle mass in asthma. Eur Respir J. 2019;54(5):1900930.

Laviolette M, Gossage DL, Gauvreau G, Leigh R, Olivenstein R, Katial R, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. (2013) 132:1086–96.e5. doi: 10.1016/j.jaci.2013. 05.020

Menzies-Gow A, Hoyte FL, Price DB, Cohen D, Barker P et al. Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab. Adv Ther 2022 May;39(5):2065-2084.

Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.Lancet 2016;388:31-44.

Le Floc'h A, Allinne J, Nagashima K, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Ralpha antibody, is required to broadly inhibit type 2 inflammation. Allergy 2020;75:1188-1204.

Lin SC, Chou HC, Chen CM, Chiang BL. Anti-thymic stromal lymphopoietin antibody suppresses airway remodeling in asthma through reduction of MMP and CTGF. Pediatr Res 2019;86:181-187.

Diver S, Khalfaoui L, Emson C, et al. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med 2021;9:1299-1312.

Berair R and Brightling CE. Asthma Therapy and Its Effect on Airway Remodelling, Drugs (2014) 74:1345–1369.

Kardas G, Kuna P and Panek M. Biological Therapies of Severe Asthma and Their Possible Effects on Airway Remodeling. Front Immunol 2020 Jun 18;11:1134.

Tsuge M, Ikeda M and Tsukahara H. Novel Lung Growth Strategy with Biological Therapy Targeting Airway Remodeling in Childhood Bronchial Asthma. Children (Basel). 2022 Aug 19;9(8):1253.

Thomas D, McDonald VM, Pavord ID and Gibson PG. Asthma remission- what is it and how can it be achieved?. Eur Respir. 2022 Mar 31;2102583.

Menzies-Gow A, Bafadhel M, Busse WW, Casale TB, Kocks JWH et al. An expert consensus framework for asthma remission as a treatment goal. J Allergy Clin Immunol. 2020 Mar;145(3):757-765.


Enlaces refback

  • No hay ningún enlace refback.